- •Pediatric Retina
- •Preface
- •1: Development of the Retina
- •1.1 To suppose that the eye . . . could have been formed by natural selection, seems, I freely confess, absurd . . .1
- •1.2 Good order is the foundation of all things2
- •1.3 All that you touch you Change. All that Change Changes you3
- •1.4 Men are born with two eyes, but only one tongue, in order that they should see twice as much as they say4
- •1.7 More than Meets the Optic Vesicle6
- •1.9 Focusing on the Fovea: A Marvel of Development
- •1.10 Nature and Books belong to the eyes that see them7
- •References
- •2: Anatomy and Physiology of the Retina
- •2.1 Introduction
- •2.2 Anatomy of the Retina
- •2.2.2 Cellular Organization of the Retina
- •2.2.2.1 Retinal Pigment Epithelium
- •2.2.2.2 Photoreceptors
- •2.2.2.3 Interneuron Cells
- •2.2.2.4 Ganglion Cells
- •2.2.2.5 Glial Cells
- •2.2.3.1 Bruch’s Membrane
- •2.2.3.2 Retinal Pigment Epithelium
- •2.2.3.3 Photoreceptor Layer
- •2.2.3.4 External Limiting Membrane
- •2.2.3.5 Outer Nuclear Layer
- •2.2.3.6 Outer Plexiform Layer
- •2.2.3.7 Inner Nuclear Layer
- •2.2.3.8 Inner Plexiform Layer
- •2.2.3.9 Ganglion Cell Layer
- •2.2.3.10 Nerve Fiber Layer
- •2.2.5 Blood Supply of the Retina
- •2.2.5.1 Choroidal Circulation
- •2.2.5.2 Hyaloid Circulation
- •2.2.5.3 Retinal Circulation
- •2.2.5.5 Regulation of Blood Flow to the Retina
- •2.2.6 Optic Nerve
- •2.2.6.1 Physiology and Development
- •2.3 Physiology of the Retina
- •2.3.1 The Retinal Pigment Epithelium
- •2.3.3 Image-Forming Visual System
- •2.3.3.1 Detection of Photons by Visual Pigment in the Photoreceptor Cell
- •2.3.3.2 Light Activation of the Photopigment
- •2.3.4 Nonimage-Forming Visual System
- •2.3.5 Targets of Retinal Projections
- •2.4 Retinal Development
- •2.4.2 Foveal Development
- •References
- •3.1 Full-Field ERG
- •3.1.1.1 Rod Response
- •3.1.1.2 Standard Combined Response
- •3.1.1.3 Oscillatory Potentials
- •3.1.1.4 Single-Flash Cone Response
- •3.1.1.5 Light-Adapted Flicker Response
- •3.1.2 Repeat Variability
- •3.1.4 Clinical Uses of the Full-Field ERG
- •3.1.4.2 Stationary Night Blindness
- •3.1.4.3 Enhanced S-Cone Syndrome
- •3.1.4.4 Leber Congenital Amaurosis
- •3.2 Focal and Multifocal ERG
- •References
- •4: Retinopathy of Prematurity (ROP)
- •4.1 Introduction
- •4.2 History
- •4.3 Classification
- •4.4 Incidence
- •4.5 Natural History and Prognosis
- •Disease with Little or No Risk
- •Disease with Moderate Risk
- •Disease with High Risk
- •4.6 Pathogenesis
- •4.7 Screening
- •4.8 Management
- •4.9 Prevention
- •4.10 Interdiction
- •4.11 Corrective Therapy
- •4.12 Mitigation
- •4.13 Medicolegal Considerations
- •4.14 Conclusion
- •References
- •5: Optic Nerve Malformations
- •5.1 Optic Nerve Hypoplasia
- •5.1.1 Overview/Clinical Significance
- •5.1.2 Classification
- •5.1.3 Genetics
- •5.1.4 Pathophysiology
- •5.1.5 Natural History
- •5.1.6 Diagnosis
- •5.1.7 Treatment
- •5.2 Morning Glory Disc Anomaly
- •5.2.1 Overview/Clinical Significance
- •5.2.2 Classification
- •5.2.3 Genetics
- •5.2.4 Pathophysiology
- •5.2.5 Natural History
- •5.2.6 Diagnosis
- •5.2.7 Treatment
- •5.2.8 Associations and Complications
- •5.3 Optic Nerve Head Pits
- •5.3.1 Introduction
- •5.3.2 Overview with Clinical Significance
- •5.3.3 Classification
- •5.3.4 Genetics
- •5.3.5 Pathophysiology
- •5.3.6 Incidence
- •5.3.8 Diagnosis and Diagnostic Aids
- •5.3.9 Treatment
- •5.3.10 Complications and Associations
- •5.4 Optic Disc Coloboma
- •5.4.1 Introduction
- •5.4.2 Genetics
- •5.4.3 Pathophysiology
- •5.4.4 Natural History and Prognosis
- •5.4.5 Diagnosis and Diagnostic Aids
- •5.4.6 Treatment
- •5.5 Optic Nerve Tumor
- •5.5.1 Glioma
- •5.5.1.1 Introduction
- •5.5.2 Overview with Clinical Significance
- •5.5.2.1 Optic Nerve Glioma
- •5.5.2.2 Optic Chiasmal Glioma
- •5.5.3 Pathophysiology
- •5.5.4 Incidence
- •5.5.6 Diagnosis
- •5.5.7 Treatment
- •5.5.8 Social and Family Impact
- •5.6.1 Introduction
- •5.6.3 Pathophysiology
- •5.6.4 Incidence
- •5.6.5 Diagnosis and Diagnostic Aids
- •5.6.6 Treatment
- •5.7 Melanocytoma
- •5.7.1 Introduction
- •5.7.2 Pathophysiology
- •5.7.3 Natural History and Prognosis
- •5.7.4 Diagnosis and Diagnostic Aids
- •5.7.5 Treatment
- •5.8 Metastatic Tumors: Leukemia
- •5.8.1 Introduction
- •5.8.2 Pathophysiology
- •5.8.3 Natural History and Prognosis
- •5.8.4 Treatment
- •5.8.4.1 Other Elevated Disc Anomalies
- •5.9 Drusen
- •5.9.1 Introduction
- •5.9.2 Pathophysiology
- •5.9.3 Natural History and Prognosis
- •5.9.4 Diagnosis and Diagnostic Aids
- •5.10 Hyperopia
- •5.11 Persistence of the Hyaloid System
- •5.12 Tilted Disc
- •5.12.1 Introduction
- •5.12.2 Historical Context
- •5.12.3 Overview with Clinical Significance
- •5.12.4 Genetics
- •5.12.5 Pathophysiology
- •5.12.6 Incidence
- •5.13 Myelinated Nerve Fibers
- •5.13.1 Introduction
- •5.13.2 Genetics
- •5.13.3 Pathophysiology
- •5.13.4 Incidence
- •References
- •6.1.1 Albinism
- •6.1.1.1 Disorders Specific to Melanosomes
- •Hermansky–Pudlak Syndrome
- •Chediak–Higashi Syndrome
- •Diagnosis and Treatment
- •6.1.2 Gyrate Atrophy
- •6.1.3 Cystinosis
- •6.1.3.1 Primary Hyperoxaluria
- •6.2.1 The Gangliosidoses
- •6.2.2 GM1 Gangliosidosis
- •6.2.3 GM2 Gangliosidosis
- •6.2.3.1 Tay–Sachs Disease
- •6.2.4 Sandhoff Disease
- •6.2.5 Niemann–Pick Disease
- •6.2.7 Type C Niemann–Pick Disease
- •6.2.8 Fabry Disease
- •6.2.9 Farber Lipogranulomatosis
- •6.2.10 The Mucopolysaccharidoses
- •6.2.10.1.1 MPS I H: Hurler Syndrome
- •6.2.10.1.2 MPS I S: Scheie Syndrome
- •6.2.10.1.3 MPS I H/S: Hurler–Scheie Syndrome
- •6.2.10.2 MPS II: Hunter Syndrome
- •6.2.10.3 MPS III: Sanfilippo Syndrome
- •6.2.10.4 MPS IV: Morquio Syndrome
- •6.2.10.5 MPS VI: Maroteaux–Lamy Syndrome
- •6.2.10.6 MPS VII: Sly Syndrome
- •6.3 Disorders of Glycoprotein
- •6.3.1 Sialidosis
- •6.4 Disorders of Peroxisomes
- •6.4.1 Refsum Disease
- •References
- •7: Phacomatoses
- •7.1 Introduction
- •7.2 Neurofibromatosis
- •7.2.1 Neurofibromatosis Type 1
- •7.2.1.1 Introduction
- •7.2.1.2 Historical Context
- •7.2.1.3 Overview with Clinical Significance
- •7.2.1.4 Genetics
- •7.2.1.5 Natural History and Prognosis
- •7.2.1.6 Signs and Symptoms
- •7.2.2 Ocular Manifestations
- •7.2.2.1 Lisch Nodules
- •7.2.2.2 Optic Pathway Glioma
- •7.2.2.3 Neurofibroma of the Eyelid and Orbit
- •7.2.3 Systemic Manifestations
- •7.2.3.1 Café-au-lait Spot
- •7.2.3.2 Neurofibroma
- •7.2.3.3 CNS Abnormality
- •Diagnosis and Diagnostic Aids
- •Treatment
- •Social and Family Impact
- •7.2.4 Neurofibromatosis Type 2 (NF2)
- •7.2.4.1 Introduction
- •7.2.4.2 Historical Context
- •7.2.4.3 Overview with Clinical Significance
- •7.2.4.4 Classification
- •7.2.4.5 Genetics
- •7.2.4.6 Incidence
- •7.2.4.7 Natural History and Prognosis
- •7.2.4.8 Signs and Symptoms
- •Ocular Findings
- •Systemic Findings
- •Vestibular Schwannoma
- •Diagnosis and Diagnostic Aids
- •Treatment
- •Complications and Associations
- •Social and Family Impact
- •7.3 Von Hippel–Lindau Disease
- •7.3.1 Introduction
- •7.3.2 Historical Context
- •7.3.3 Overview with Clinical Significance
- •7.3.4 Classification
- •7.3.5 Genetics
- •7.3.6 Pathophysiology
- •7.3.7 Incidence
- •7.3.8 Natural History and Prognosis
- •7.3.9 Signs and Symptoms
- •7.3.9.1 Ocular Manifestations
- •Retinal Capillary Hemangioma
- •7.3.9.2 Systemic Manifestations
- •CNS Hemangioma
- •Renal Cell Carcinoma
- •Pheochromocytoma
- •Pancreatic Cystadenoma and Islet Cell Tumors
- •Epididymis Cystadenoma
- •7.3.10 Diagnosis and Diagnostic Aids
- •7.3.10.1 Coats’ Disease
- •7.3.10.2 Racemose Hemangioma
- •7.3.10.3 Retinal Cavernous Hemangioma
- •7.3.10.4 Retinal Macroaneurysm
- •7.3.10.5 Vasoproliferative Tumor
- •7.3.11 Fluorescein Angiography
- •7.3.12 Indocyanine Green Angiography
- •7.3.13 Ultrasonography
- •7.3.14 Magnetic Resonance Imaging
- •7.3.16 Treatment
- •7.3.17 Observation
- •7.3.18 Laser Photocoagulation
- •7.3.19 Cryotherapy
- •7.3.21 Plaque Radiotherapy
- •7.3.22 Proton Beam Radiotherapy
- •7.3.24 Enucleation
- •7.3.25 Social and Family Impact
- •7.4 Tuberous Sclerosis Complex
- •7.4.1 Introduction
- •7.4.2 Historical Context
- •7.4.3 Overview with Clinical Significance
- •7.4.4 Classification
- •7.4.5 Genetics
- •7.4.6 Incidence
- •7.4.7 Natural History and Prognosis
- •7.4.8 Signs and Symptoms
- •7.4.8.1 Ocular Findings
- •Retinal Astrocytic Hamartoma
- •7.4.8.2 Systemic Findings
- •Dermatologic Manifestations
- •Neurologic Manifestations
- •Visceral Manifestations
- •Diagnosis and Diagnostic Aids
- •Treatment
- •Social and Family Impact
- •7.5 Sturge-Weber Syndrome
- •7.5.1 Introduction
- •7.5.2 Historical Context
- •7.5.3 Overview with Clinical Significance
- •7.5.4 Incidence
- •7.5.5 Genetics
- •7.5.6 Pathophysiology
- •7.5.7 Natural History and Prognosis
- •7.5.8 Signs and Symptoms
- •7.5.8.1 Diffuse Choroidal Hemangioma
- •7.5.8.2 Glaucoma
- •7.5.8.3 Nevus Flammeus
- •7.5.8.4 Leptomeningeal Hemangiomatosis
- •7.5.8.5 Diagnosis and Diagnostic Aids
- •7.5.8.6 Treatment
- •7.5.8.7 Social and Family Impact
- •7.6 Wyburn-Mason Syndrome
- •7.6.1 Introduction
- •7.6.2 Historical Context
- •7.6.3 Overview with Clinical Significance
- •7.6.4 Classification
- •7.6.5 Genetics
- •7.6.6 Pathophysiology
- •7.6.7 Natural History and Prognosis
- •7.6.8 Signs and Symptoms
- •7.6.8.1 Ocular Findings
- •Retinal Arteriovenous Malformation
- •Diagnosis and Diagnostic Aids
- •Treatment
- •7.6.9 Ataxia Telangiectasia
- •7.6.9.1 Introduction
- •7.6.9.2 Historical Context
- •7.6.9.3 Overview with Clinical Significance
- •7.6.9.4 Classification
- •7.6.9.5 Genetics
- •7.6.9.6 Incidence
- •7.6.9.7 Natural History and Prognosis
- •7.6.9.8 Signs and Symptoms
- •7.6.9.9 Diagnosis and Diagnostic Aids
- •7.6.9.10 Treatment
- •7.6.9.11 Social and Family Impact
- •7.7 Retinal Caverous Hemangioma
- •7.7.1 Introduction
- •7.7.2 Historical Context
- •7.7.3 Overview with Clinical Significance
- •7.7.4 Genetics
- •7.7.5 Incidence
- •7.7.6 Natural History and Prognosis
- •7.7.7 Signs and Symptoms
- •7.7.7.1 Ocular Findings
- •7.7.7.2 Systemic Findings
- •Cutaneous Lesions
- •Diagnosis and Diagnostic Aids
- •Treatment
- •References
- •8.1 Introduction
- •8.2 Embryology
- •8.3 Clinical Findings
- •8.3.1 Primary anomalies
- •8.3.2 Secondary findings
- •8.3.3 Differential Diagnosis
- •8.3.3.1 Ancillary Tests
- •8.3.3.2 Prognosis
- •8.3.3.3 Treatment
- •8.4 Practical Surgical Issues
- •8.4.1 The Posterior Surgery
- •References
- •9.1 Introduction
- •9.2 Retinoblastoma Presentation SOP
- •9.2.1 Objective
- •9.2.2 Applicability
- •9.2.3 Scope
- •9.2.4 Clinical Significance
- •9.2.5 Procedures
- •9.2.6 Consequences
- •9.2.7 Related SOPs
- •9.3.1 Objectives
- •9.3.2 Applicability
- •9.3.3 Scope
- •9.3.4 Clinical Significance
- •9.3.5 Procedures
- •9.3.6 Consequences
- •9.3.7 Related SOPs
- •9.4 Genetics of Retinoblastoma SOP
- •9.4.1 Objective
- •9.4.2 Applicability
- •9.4.3 Scope
- •9.4.4 Clinical Significance
- •9.4.5 Procedure
- •9.4.6 Consequences
- •9.4.7 Related SOPs
- •9.5 Screening of Relatives SOP
- •9.5.1 Objective
- •9.5.2 Applicability
- •9.5.3 Scope
- •9.5.4 Clinical Significance
- •9.5.5 Procedure
- •9.5.6 Consequences
- •9.5.7 Related SOPs
- •9.6 Treatment SOP
- •9.7 Enucleation Indications SOP
- •9.7.1 Objective
- •9.7.2 Applicability
- •9.7.3 Scope
- •9.7.4 Clinical Significance
- •9.7.5 Procedure
- •9.7.6 Consequences
- •9.7.7 Related SOPs
- •9.8 Enucleation Technique SOP
- •9.8.1 Objectives
- •9.8.2 Applicability
- •9.8.3 Scope
- •9.8.4 Clinical Significance
- •9.8.5 Procedure
- •9.8.6 Consequences
- •9.8.7 Related SOPs
- •9.9.1 Objectives
- •9.9.2 Applicability
- •9.9.3 Scope
- •9.9.4 Clinical Significance
- •9.9.5 Procedure
- •9.9.6 Consequences
- •9.9.7 Related SOPs
- •9.10 Histopathology Analysis SOP
- •9.10.1 Objectives
- •9.10.2 Applicability
- •9.10.3 Scope
- •9.10.4 Clinical Significance
- •9.10.5 Procedure
- •9.10.6 Consequences
- •9.10.7 Related SOPs
- •9.11 Cryotherapy SOP
- •9.11.1 Objectives
- •9.11.2 Applicability
- •9.11.3 Scope
- •9.11.4 Clinical Significance
- •9.11.5 Procedure
- •9.11.6 Consequences
- •9.11.7 Related SOPs
- •9.12 Laser Therapy SOP
- •9.12.1 Objective
- •9.12.2 Applicability
- •9.12.3 Scope
- •9.12.4 Clinical Significance
- •9.12.5 Procedure
- •9.12.6 Consequences
- •9.12.7 Related SOPs
- •9.13 Local Chemotherapy SOP
- •9.13.1 Objectives
- •9.13.2 Applicability
- •9.13.3 Scope
- •9.13.4 Clinical Significance
- •9.13.5 Procedure
- •9.13.6 Consequences
- •9.13.7 Related SOPs
- •9.14 Systemic Chemotherapy SOP
- •9.14.1 Objectives
- •9.14.2 Applicability
- •9.14.3 Scope
- •9.14.4 Clinical Significance
- •9.14.5 Procedure
- •9.14.6 Consequences
- •9.14.7 Related SOPs
- •9.15 Radiation SOP
- •9.15.1 Objective
- •9.15.2 Applicability
- •9.15.3 Scope
- •9.15.4 Clinical Significance
- •9.15.5 Procedure
- •9.15.6 Consequences
- •9.15.7 Related SOPs
- •9.16.1 Objective
- •9.16.2 Applicability
- •9.16.3 Scope
- •9.16.4 Clinical Significance
- •9.16.5 Procedure
- •9.16.6 Consequences
- •9.16.7 Related SOPs
- •9.17 Follow-Up SOP
- •9.17.1 Objective
- •9.17.2 Applicability
- •9.17.3 Scope
- •9.17.4 Clinical Significance
- •9.17.5 Procedure
- •9.17.6 Consequences
- •9.17.7 Related SOPs
- •References
- •10: Coats’ Disease
- •10.1 Overview
- •10.3 Clinical Aspects
- •10.3.1 Demographics
- •10.3.2 Ocular Findings
- •10.4 Pathology and Pathophysiology
- •10.5 Genetics
- •10.6 Natural History
- •10.8 Management
- •10.9 Systemic Associations
- •10.10 Social and Family Impact
- •10.11 Future Treatment
- •References
- •11.1.1 Stargardt Macular Dystrophy
- •11.1.1.1 Clinical Features: STGD
- •11.1.1.2 Diagnostic Features: STGD
- •11.1.1.3 Differential Diagnosis: STGD
- •11.1.1.4 Inherited Forms: STGD
- •11.1.2 Best Macular Dystrophy
- •11.1.2.1 Clinical Features: BMD
- •11.1.2.2 Diagnostic Features: BMD
- •11.1.2.3 Differential Diagnosis: BMD
- •11.1.2.4 Inherited Forms: BMD
- •11.1.3 Juvenile X-Linked Retinoschisis
- •11.1.3.1 Clinical Features: JXRS
- •11.1.3.2 Diagnostic Features: JXRS
- •11.1.3.3 Differential Diagnosis: JXRS
- •11.1.3.4 Inherited Forms: JXRS
- •11.2.2 Molecular Genetic Testing
- •11.2.3.1 ABCR
- •11.2.3.2 ELOVL4
- •11.2.3.3 PROM1
- •11.2.3.4 BEST-1
- •11.3.1 STGD
- •11.3.3 JXRS
- •11.4.1 STGD Models
- •11.4.2 BMD Models
- •11.4.3 JXRS Models
- •11.5 Phenotypic Diversity
- •11.6 Potential Therapeutics for Juvenile Macular Degenerations
- •References
- •12: Generalized Inherited Retinal Dystrophies
- •12.1 Introduction
- •12.2 Historical Context
- •12.4.1 Retinitis Pigmentosa
- •12.4.1.1 Overview with Clinical Significance
- •12.4.1.2 Genetics
- •12.4.1.3 Pathophysiology
- •12.4.1.4 Prevalence
- •12.4.1.5 Patient History and Evaluation
- •12.4.1.6 Diagnostic Testing
- •12.4.1.7 Treatment
- •12.4.2 Congenital Leber Amaurosis
- •12.4.2.1 Genetics
- •12.4.2.2 Pathophysiology
- •12.4.2.3 Incidence/Prevalence
- •12.4.2.4 Natural History and Prognosis
- •12.4.2.5 Diagnostic Testing
- •12.4.2.6 Treatment
- •12.4.3.1 Genetics
- •12.4.3.2 Pathophysiology
- •12.4.3.3 Incidence
- •12.4.3.4 Natural History and Prognosis
- •12.4.3.5 Diagnostic Testing
- •12.4.3.6 Treatment
- •12.4.3.7 Achromatopsia
- •12.4.4.1 Genetics
- •12.4.4.2 Pathophysiology
- •12.4.4.3 Incidence
- •12.4.4.4 Evaluation and Prognosis
- •12.4.4.5 Diagnostic Testing
- •12.4.4.6 Treatment
- •12.4.4.7 Complications and Disease Associations
- •12.4.4.8 Social Considerations
- •References
- •13: Vitreoretinal Dystrophies
- •13.1 Stickler Syndrome
- •13.1.1 Introduction
- •13.1.2 Historical Context
- •13.1.3 Overview with Clinical Significance
- •13.1.4 Classification
- •13.1.5 Genetics
- •13.1.6 Pathophysiology
- •13.1.7 Incidence
- •13.1.8 Natural History and Prognosis of STK (Signs, Symptoms, Timing, etc.)
- •13.1.9 Diagnosis and Diagnostic Aids
- •13.1.10 Treatment
- •13.1.11 Complications and Associations
- •13.1.12 Social and Family Impact
- •13.2 Wagner Disease
- •13.2.1 Introduction
- •13.2.2 Historical Context
- •13.2.3 Overview with Clinical Significance
- •13.2.4 Classification
- •13.2.5 Genetics
- •13.2.6 Pathophysiology
- •13.2.7 Incidence
- •13.2.9 Diagnosis and Diagnostic Aids
- •13.2.10 Treatment
- •13.2.11 Complications and Associations
- •13.2.12 Social and Family Impact
- •13.3 Juvenile X-Linked Retinoschisis
- •13.3.1 Introduction
- •13.3.2 Historical Context
- •13.3.3 Overview with Clinical Significance
- •13.3.4 Classification
- •13.3.5 Genetics
- •13.3.6 Pathophysiology
- •13.3.7 Incidence
- •13.3.9 Diagnosis and Diagnostic Aids
- •13.3.10 Treatment
- •13.3.11 Complications and Associations
- •13.3.12 Social and Family Impact
- •13.4.1 Introduction
- •13.4.2 Historical Context
- •13.4.3 Overview with Clinical Significance
- •13.4.4 Classification
- •13.4.5 Genetics
- •13.4.6 Pathophysiology
- •13.4.7 Incidence
- •13.4.9 Diagnosis and Diagnostic Aids
- •13.4.10 Treatment
- •13.4.11 Complications and Associations
- •13.4.12 Social and Family Impact
- •13.5 Goldmann-Favre Syndrome
- •13.5.1 Introduction
- •13.5.2 Historical Context
- •13.5.3 Overview with Clinical Significance
- •13.5.4 Classification
- •13.5.5 Genetics
- •13.5.6 Pathophysiology
- •13.5.7 Incidence
- •13.5.9 Diagnosis and Diagnostic Aids
- •13.5.10 Treatment
- •13.5.11 Complications and Associations
- •13.5.12 Social and Family Impact
- •13.6 Incontinentia Pigmenti (IP)
- •13.6.1 Introduction
- •13.6.2 Historical Context
- •13.6.3 Overview with Clinical Significance
- •13.6.4 Classification
- •13.6.5 Genetics
- •13.6.6 Pathophysiology
- •13.6.7 Incidence
- •13.6.9 Diagnosis and Diagnostic Aids
- •13.6.10 Treatment
- •13.6.11 Complications and Associations
- •13.6.12 Social and Family Impact
- •13.7.9 Diagnosis and Diagnostic Aids
- •13.7.10 Treatment
- •13.7.11 Complications and Associations
- •13.7.12 Social and Family Impact
- •References
- •14.1 Introduction
- •14.2 Clinical Course
- •14.3 Differential Diagnosis
- •14.4 Pathology
- •14.5 Selected Conditions
- •14.6 Treatment
- •References
- •15: Proliferative Retinopathies in Children
- •15.1 Introduction
- •15.2 Historical Context
- •15.3 Overview with Clinical Significance
- •15.4 Classification
- •15.5 Genetics (table 15.1)
- •15.5.1 Pathophysiology
- •15.5.2 Natural History and Prognosis
- •15.5.3 Diabetes Mellitus
- •15.5.4 Sickle Cell Disease
- •15.5.5 Incontinentia Pigmenti
- •15.6 Complications and Associations
- •15.7 Social and Family Impact
- •References
- •16: Infectious Diseases of the Pediatric Retina
- •16.1 Introduction
- •16.2 Protozoal Diseases
- •16.2.1 Toxoplasma gondii
- •16.2.1.1 Life Cycle and Transmission
- •16.2.1.2 Epidemiology
- •16.2.1.3 Congenital Infection
- •16.2.1.4 Ocular Disease
- •16.2.1.5 Immunocompromised Patients
- •16.2.1.6 Diagnosis of Ocular Toxoplasmosis
- •16.2.1.7 Treatment
- •16.2.1.8 Treatment in Special Situations
- •16.3 Viral Diseases
- •16.3.1 Cytomegalovirus Retinitis
- •16.3.1.1 Congenital CMV Infection
- •16.3.1.2 Ocular Manifestations
- •16.3.1.3 Acquired CMV Infection
- •16.3.1.4 Ocular Disease
- •16.3.1.5 Pathology
- •16.3.1.6 Diagnosis
- •16.3.1.7 Therapy
- •16.3.2 Varicella Zoster Virus
- •16.3.2.1 Ocular Manifestations
- •16.3.3 Herpes Simplex Virus
- •16.3.3.1 Ocular Disease
- •16.3.4 Acute Retinal Necrosis
- •16.3.4.1 Clinical Presentation
- •16.3.4.2 Diagnosis
- •16.3.4.3 Treatment
- •16.3.5 HIV Infection
- •16.3.5.1 Ocular Manifestations
- •16.3.5.2 Noninfectious HIV Microangiopathy
- •16.3.6 Measles
- •16.3.7 Rubella
- •16.3.7.1 Congenital Rubella Syndrome
- •16.4 Parasitic Infection
- •16.4.1 Toxocariasis
- •16.4.1.1 Ocular Involvement
- •16.4.1.2 Diagnosis
- •16.4.1.3 Differential Diagnosis
- •16.4.1.4 Treatment
- •16.4.2 Onchocerciasis
- •16.4.2.1 Ocular Manifestations
- •16.4.2.2 Diagnosis and Treatment
- •16.5 Bacterial Diseases
- •16.5.1 Syphilis
- •16.5.1.1 Clinical Manifestations
- •16.5.1.2 Congenital Syphilis
- •16.5.1.3 Acquired Syphilis
- •16.5.1.4 Diagnosis
- •16.5.1.5 Syphilis and AIDS
- •16.5.1.6 Treatment
- •16.5.2 Tuberculosis
- •16.5.2.1 Ocular Manifestation
- •16.5.2.2 Diagnosis
- •16.5.2.3 Tuberculosis and AIDS
- •16.5.2.4 Treatment
- •16.6 Rare Childhood Bacterial Diseases
- •16.6.1 Brucellosis
- •16.6.2 Leptospirosis
- •16.6.3 Lyme Disease
- •16.6.4 Cat Scratch Disease
- •16.7 Fungal Disease
- •16.7.1 Histoplasmosis
- •16.7.1.1 Ocular Histoplasmosis Syndrome (OHS)
- •16.7.1.2 Diagnosis and Treatment
- •16.7.2 Fungal Endophthalmitis
- •16.7.2.1 Endogenous Fungal Endophthalmitis
- •Candidiasis
- •Ocular Features
- •Diagnosis and Treatment
- •Rare Causes of Endogenous Endophthalmitis
- •Aspergillosis
- •Cryptococcosis
- •Histoplasmosis
- •Pneumocystis carinii
- •North American Blastomycosis
- •Coccidiomycosis
- •Other Fungal Infections
- •16.7.2.2 Exogenous Fungal Endophthalmitis
- •16.8 Rickettsial Disease
- •References
- •17.1 Introduction
- •17.2 Age of Victims
- •17.4 Perpetrators
- •17.5 Brain Injury
- •17.6 Skeletal Injuries
- •17.7 Acute Ophthalmic Findings
- •17.8 Dating of Retinal Hemorrhages
- •17.9 Treatment of Retinal Hemorrhages
- •17.10 Late Ophthalmic Findings
- •17.13 The Role of the Ophthalmologist
- •References
- •18: Pediatric Retinal Trauma
- •18.1 Introduction
- •18.2 Epidemiology
- •18.3 Etiology of Trauma
- •18.3.1 Sports
- •18.3.2 Assault
- •18.3.3 Birth Trauma
- •18.3.4 Projectile Injury
- •18.3.5 Miscellaneous Causes
- •18.3.6 Sympathetic Ophthalmia
- •18.4 Closed Globe Injuries
- •18.4.1 Traumatic Macular Hole
- •18.4.2 Commotio Retinae
- •References
- •19: Pediatric Uveitis
- •19.1 General Introduction
- •19.2 Classification
- •19.3 Social and Family Impact
- •19.4 Noninfectious
- •19.4.1 Juvenile Rheumatoid Arthritis
- •19.4.1.1 Historical Context
- •19.4.1.2 Clinical Findings/Natural History
- •Subtypes of JRA (Table 19.2) .
- •Screening Guidelines
- •Pathophysiology
- •Diagnosis/Treatment
- •Genetics
- •Complications
- •19.4.2 HLA-B27-Associated Uveitis
- •19.4.2.1 Historical Context
- •19.4.2.2 Clinical Findings/Natural History
- •Pathophysiology/Genetics
- •Diagnosis/Treatment/Complications
- •19.4.3 Tub ulointerstitial Nephritis and Uveitis (TINU)
- •19.4.3.1 Historical Context
- •19.4.3.2 Clinical Findings/Natural History
- •Pathophysiology/Genetics
- •Diagnosis/Treatment/Complications
- •19.4.4 Sarcoidosis
- •19.4.4.1 Historical Context
- •19.4.4.2 Clinical Findings/Natural History
- •Pathophysiology
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.4.5 Pars Planitis
- •19.4.5.1 Historical Context
- •19.4.5.2 Clinical Findings/Natural History
- •Pathophysiology/Genetics
- •Diagnosis
- •Treatment
- •Step 1
- •Step 2
- •Step 3
- •Step 4
- •Complications
- •19.5 Infectious
- •19.5.1 Toxoplasmosis
- •19.5.1.1 Historical Context/Pathophysiology
- •19.5.1.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.5.2 Toxocariasis
- •19.5.2.1 Historical Context/Pathophysiology
- •19.5.2.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.5.3 Bartonella henselae
- •19.5.3.1 Historical Context/Pathophysiology
- •19.5.3.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.5.4.1 Historical Context/Pathophysiology
- •19.5.4.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •19.5.5 Congenital Ocular Syphilis
- •19.5.5.1 Historical Context/Pathophysiology
- •19.5.5.2 Clinical Findings/Natural History
- •Genetics
- •Diagnosis/Treatment/Complications
- •References
- •Index
8 Persistent Hyperplastic Primary Vitreous (PHPV) |
195 |
|
|
Ciliary body: Ciliary processes are typically elongated and drawn centrally. This can occur in isolation but more commonly occurs when the ciliary processes are incorporated into a RLM. These processes may also drag peripheral retina into the RLM.
Glaucoma: Many eyes with PFV develop secondary angle closure glaucoma. The trabecular meshwork in PFV is of the fetal type in 56% and often incompletely cleaved [4, 18]. Additionally, some eyes with PFV have extension of Descemet’s membrane onto the trabecular meshwork surface [18]. Peripheral anterior synechiae have been reported in 26% of eyes enucleated for PFV [12, 18] and the anterior chamber often shallows as the lens becomes cataractous, occluding the angle. Reese felt that the abnormalities of the angle itself did not play the primary role in the development of glaucoma and that secondary changes were primarily responsible [2, 18]. Intractable glaucoma is a common reason for enucleation in older patients with PFV, often in their teenage years [18].
Uveitis: A phacoanaphylactoid reaction may develop, leading to an erroneous diagnosis of uveitis [20]. Of all cases of PFV, 6.5% are initially diagnosed as uveitis [18].
Strabismus: Boniuk and Freedman reported strabismus as the presenting sign in 8% of patients presenting with PFV [18].
Hyphema: 6.5% of patients with PFV present with this finding [18]. The hyphema is likely due to persistence of the fine vessels of the anterior TVL [4].
Vitreous hemorrhage: Patients with PFV can develop vitreous hemorrhages. These hemorrhages can contribute to the glaucoma seen in patients with PFV [21].
including dilated indirect ophthalmoscopy. The patients with RB or in whom the possibility of RB cannot be excluded require prompt referral to a tertiary referral center for further management.
A definitive diagnosis is crucial in determining the appropriate treatment for patients with leukocoria. Most importantly, RB must be excluded with certainty since the treatments for PFV, ROP, or Coats’ disease include intraocular surgery which may have grave consequences in patients with RB. On the other hand, enucleation continues to be a widely employed form of treatment for the eyes with RB but is used sparingly in patients with other forms of leukocoria.
The following diseases are most commonly included in the differential diagnosis of leukocoria:
•Retinoblastoma
•Retinopathy of prematurity (ROP) – stage 5 with total retinal detachment and fibrous membranes
•PFV
•Coats disease
•Toxocariasis
•Vitreous hemorrhage
Other diseases that may present as leukocoria are:
•Posterior cataract
•Choroidal coloboma
•Uveitis
•Retinal detachment
•Congenital retinal folds
•Retinal dysplasia
•Incontenentia pigmenti
•Other tumors (Hemartomas, choroidal hemangioma, and meduloepithelioma)
Table 8.1 presents the major differentiating features of the important disease entities that may be confused with end stage PFV.
8.3.3 Differential Diagnosis
The advanced stage of PFV results in “leukocoria” a word that translates as white pupil from Greek. Among all causes of leukocoria, delayed diagnosis and treatment of retinoblastoma (RB) results in the greatest therapeutic and prognostic consequences. Therefore, all ophthalmologists must act from a very high index of suspicion of RB in all patients with leukocoria. Minimally, all pediatric patients who present with leukocoria of recent onset should undergo a thorough ophthalmologic examination
8.3.3.1 Ancillary Tests
Several ancillary tests can be performed to either confirm the diagnosis of PFV or more importantly to differentiate PFV from other diseases such as RB and ROP. The majority of ancillary tests are particularly useful when media opacity precludes a clear view of posterior segment of the eye. USG, CT scan, and MRI are the major diagnostic modalities used in the investigation of patients with leukocoria.
Table 8.1 Differential diagnostic findings in PFV and major imitators |
|
|
|
||
|
PFV |
RB |
ROP (stage 4 or 5) |
Coats disease |
Toxocariasis |
History |
|
|
|
|
|
Gestational age |
Full term |
Full term |
Premature |
Full term |
Full term |
Age of presentation |
Usually noted days to weeks |
Clinically apparent several |
Noted at birth or within |
Apparent at 2–10 years |
Few years after birth |
|
after birth |
months to years after birth |
6 months |
of age |
(>3 years) |
History of contact |
– |
– |
– |
– |
History of contact |
|
|
|
|
|
with puppies and |
|
|
|
|
|
eating dirt |
Family history |
family history may be |
Family history may be |
– |
– |
– |
|
positive in bilateral cases |
positive |
|
|
|
|
associated with systemic |
|
|
|
|
|
syndromes |
|
|
|
|
Presenting history |
Strabismus |
Strabismus |
Strabismus |
Strabismus |
Strabismus |
Clinical features |
|
|
|
|
|
Bilaterality |
Unilateral (90%) |
May be bilateral (67% |
Bilateral but may be |
Unilateral (80-90%) |
Unilateral |
|
|
unilateral) |
asymmetric |
|
|
Ocular dimensions |
Microphthalmos (66-84%) |
Normal size or may have |
Normal size or microphthalmol |
Normal size or may have |
Normal size |
|
|
buphthalmos |
in stage 4 or 5 |
buphthalmos |
|
Cornea |
Microcornea |
Normal size |
Normal size |
Normal size |
Normal size |
Iris |
Engorged, and prominent |
NVI (50%), heterochromia |
NVI or pupillary membranes |
NVI may be present |
– |
|
iris vessels |
|
|
|
|
Anterior chamber |
Shallow anterior chamber |
May have tumor seeds |
Shallow anterior chamber |
Shallow anterior chamber |
May have |
|
|
(pseudohypopyon) |
|
|
inflammation |
Glaucoma |
Secondary angle closure |
May have glaucoma |
May develop angle closure |
Glaucoma in later stages |
– |
|
glaucoma |
|
glaucoma in the later stages |
|
|
Ciliary body |
Elongated ciliary processes |
– |
Elongated ciliary processes in |
– |
– |
|
|
|
stage 5 |
|
|
Lens |
Cataract in late stages |
– |
– |
– |
– |
|
Tunica vasculosa lentis may |
– |
Tunica vasculosa lentis may be |
– |
– |
|
be present |
|
present |
|
|
Anterior vitreous |
Retrolental mass |
Retina against back of the |
Retina against back of the lens |
Retina against back of the |
Retina against back |
|
may be seen |
lens in exo or in endophytic |
may be present |
lens may be seen |
of the lens may |
|
|
type tumor |
|
|
be seen |
196
.al et Buerk .M.B
Posterior segment |
Remnants of hyaloid artery, |
Exo or endophytic tumor |
Immature retina or ROP |
Intraretinal exudation, |
Vitreous reaction and |
|
and vitreous bands |
|
|
peripheral telengiactasia |
toxocara granuloma |
|
Tractional RD |
Exudative RD |
Tractional RD |
Exudative RD |
Tractional RD |
Genetics |
No genetic predisposition |
Familial RB is recessive at |
No genetic predisposition |
No genetic predisposition |
No genetic |
|
|
the molecular level but is |
|
|
predisposition |
|
|
transmitted as an autosomal |
|
|
|
|
|
dominant trait |
|
|
|
Imaging |
|
|
|
|
|
Ultrasonography |
Microphthalmos, vitreous |
Tumor with calcification, |
TRD with anterior mass |
May show subretinal |
Usually peripheral |
|
bands, and TRD |
TRD |
|
exudation and retinal |
fundus mass, TRD |
|
|
|
|
detachment |
|
CT scan |
Contrast enhanced intravitreal |
Tumor with calcification |
|
May show subretinal |
Usually peripheral |
|
tissues, subhyloid or |
|
|
exudation and retinal |
fundus mass |
|
subretinal fluid, RD, small |
|
|
detachment |
|
|
eye, small lens, may have |
|
|
|
|
|
small intraorbital optic nerve |
|
|
|
|
MRI |
T1-weighted hyperintense |
T1-weightedTumor is iso or |
– |
– |
– |
|
vitreous and subretinal space |
hyperintense than vitreous |
|
|
|
|
|
T2-weightedTumor |
|
|
|
|
|
hypointense than vitreous |
|
|
|
|
|
Pinealoma may be present |
|
|
|
Management |
|
|
|
|
|
Diagnosis |
Depends on history and |
Depends on history and |
Depends on history and clinical |
Depends on history and |
Depends on history |
|
clinical features |
clinical features |
features |
clinical features |
and clinical features |
|
Occasional imaging required |
CT scan may be useful in |
Occasional imaging required |
FA may be useful. Imaging |
Serum toxocara |
|
|
confirmation of diagnosis |
|
rarely necessary |
antibody titers and |
|
|
|
|
|
vitreous biopsy may |
|
|
|
|
|
be useful |
Treatment modali- |
Vitrectomy, lensectomy, RD |
Enucleation, Cryotherapy, |
Laser, cryotherapy, Scleral |
Laser, cryotherapy, |
Chemotherapy, |
ties employed |
repair via anterior or pars |
Laser photocoagulation, |
buckle, vitrectomy with or |
vitrectomy |
vitrectomy for RD |
|
plicata approach |
chemotherapy, TTT, EBR, |
without lensectomy |
|
repair |
|
|
plaque radiotherapy |
|
|
|
Prognosis |
In general, guarded for vision |
Prognosis for vision and life |
Guarded for vision in later |
Guarded for vision in later |
Good for vision |
|
|
improved in last decade |
stages |
stages |
|
ROP retinopathy of prematurity; RB retinoblastoma; NVI neovascularization of iris; TRD tractional retinal detachment; RD retinal detachment; USG ultrasonography; CT scan computed tomography scan; MRI magnetic resonance imaging; EBR external beam radiation; TTT transpupillary thermotherapy
(PHPV) Vitreous Primary Hyperplastic Persistent 8
197
198 |
B.M. Buerk et al. |
|
|
•Ultrasonography (USG) – The echographic findings in patients with PFV depend on the location and severity of disease. Usually, USG in PFV shows a small globe although the severity may vary. The lens is often thinner than normal with irregularity of the posterior capsule. The persistent hyaloid artery may be seen as a vitreous band that extends from the posterior surface of the lens to the optic disc and may result in tractional RD in the peripapillary area. Occasionally total RD may be observed in severe cases. USG may identify RB by showing an intraocular mass and calcification. However, the tumor and calcification can be demonstrated accurately by ultrasonographically only in 80% of patients [22]. Tumor extension into the lateral and medial aspect of the orbit and extraocular extension are difficult to diagnose by ultrasonographically [23].
•Computed tomographic scans (CT scan) – Goldberg and associates [24] and Mafee and Goldberg [25]. first described several CT scan features in eyes with PFV that may help to characterize and detect the presence of disease. They recommended the use of intravenous contrast agent and to repeat the scan in lateral decubitus position to derive maximum information. The following CT scan features were described. (1) Microphthalmos which at times may be subtle, is usually observed. (2) Unlike many cases of RB, calcification within and around the globe is absent. (3) Vitreous may show an increased density.
(4) Abnormal intravitreal tissues may enhance following intravenous administration of contrast. (5) The persistence of fetal tissue in the Cloquet’s canal or a congenital nonattachment of the retina may result in tubular, cylindrical, triangular or other forms of discrete intravitreal densities. (6) The serosanguineous fluid in the subhyaloid space or subretinal space may show shifting fluid levels within the vitreous cavity in the decubitus position. (7) The lens may be small and irregular in shape and the anterior chamber may be shallow. (8) Either normal or slightly smaller intraorbital segment of the optic nerve may be observed. These authors also underlined the ease with which the affected eye can be compared with the fellow normal eye by using CT scans in comparison to USG. The CT scan is particularly important in confirming the presence of intraocular calcification which is a hallmark of RB. A possible drawback of CT scan may be its potential for radiation toxicity on the susceptible ocular tissues such as lens.
•Magnetic resonance imaging (MRI) – MRI is more sensitive and specific in differentiating the full range of conditions causing leukocoria. In patients with PFV, T1-weighted MRI images show hyperintensity of the vitreous cavity and/or subretinal space due probably to the presence of proteinaceous fluid or old blood [25]. In contrast, RB is isointense or slightly hyperintense compared with vitreous on T1-weighted and hypointense to vitreous on T2-weighted images [25]. However, the CT scan is superior to MRI for evaluation of patients with RB as the detection of calcification by MRI is not as specific as CT scan.
•Fluorescein angiography – The fluorescein angiography may provide supporting clues for the diagnosis of PFV by revealing the presence of anterior TVL, persistent pupillary membrane vasculature, or a complete or partial brittle star in the retrolental space [26]. Fluorescein angiography is particularly helpful for the diagnosis of Coats’ disease where telengiectatic retinal vessels clearly stand out as hyperfluorescent “light bulb-like” lesions.
8.3.3.2 Prognosis
The visual prognosis for patients with PFV is highly variable. Minimal disease may not have any significant visual consequences and, therefore, may not even require treatment. Mild disease involving either the posterior or anterior segment may require surgery and result in normal vision. Patients with a combination of anterior and posterior PFV with minimal posterior segment involvement may even retain some useful central vision if early surgical intervention is followed by aggressive amblyopia therapy. Advanced anterior PFV may result in severe vision loss.
8.3.3.3 Treatment
A multidisciplinary approach where retinal and pediatric ophthalmologists are involved in the treatment and follow-up of patients with PFV offers the best chance of anatomic or functional success. The location and severity of PFV dictates the treatment strategies. In severe cases surgical intervention may not restore vision, but surgery may help to limit the consequences of angle closure glaucoma by removing the retrolental
8 Persistent Hyperplastic Primary Vitreous (PHPV) |
199 |
|
|
tissue and associated cataract. Patients with very severe PFV resulting in end stage glaucoma or severely disorganized globe may require enucleation. Cosmetically acceptable appearance in this group of patients may be achieved by fitting an appropriate prosthesis.
Some historical prognostic indicators for favorable visual results include a young patient, a normal posterior segment, and PFV that has not progressed to flat anterior chamber, extensive synechiae, or intractable glaucoma [3, 27, 28].
Historically, the most frequent surgical indications in eyes with PFV included shallowing of anterior chamber, progressive cataract formation, progressive traction of the ciliary body, intractable glaucoma, and RD. The suggested surgical approaches for the management of PFV include excision of the retrolental tissue and removal of cataract by utilizing a variety of vitrectomy instruments via a limbal or pars plana/pars plicata approach.
Historically, the anatomic and visual success has been linked to the degree of posterior segment involvement and the severity of disease. In the past, a twostage surgical approach was utilized with an intent to preserve the globe and clear the pupillary axis. A vision of 20/400 or better was rarely obtained [29]. In 1986, Karr and Scott [27] reported that 8 of 18 patients with PFV in their series achieved 20/200 or better vision after surgical treatment. They recommended early surgical intervention followed by aggressive amblyopia therapy, but observed the poor outcome in eyes with posteriorsegmentinvolvement.Outcomeshaveimproved with advances in microsurgical techniques, new developments in pediatric aphakic contact lenses, and an early and aggressive amblyopia therapy. Stark et al. [30] reported on the 7 eyes of 7 patients that were operated on by closed-eye vitrectomy techniques through a limbal approach. Six of 7 eyes were treated by amblyopia therapy, out of which, one eye achieved a vision of 20/60 and another one 20/200. The remaining 5 of 7 eyes had count fingers to hand motion vision. However, in 3 of these 5 eyes, reduced vision was attributed to the preexisting macular or optic nerve abnormality. All seven operated eyes were considered surgical/anatomic successes by the authors.
In 1998, Mittra and associates [31], in a retrospective chart review described 14 patients who underwent surgical treatment of combined anterior and posterior PFV via pars plana or limbal approach and were followed for 22 months postoperatively. Twelve out of a
total 14 patients were thought to have visual potential and therefore were treated with aggressive amblyopia therapy. Ten of these 12 patients (83%) achieved a visual acuity of 20/300 or better and 8 (66%) obtained a final vision of 20/100 or better. More importantly, not a single patient had a vision of less than 5/200. By historic comparison, these authors found their results closely approximated those achieved after surgery for unilateral congenital cataract without PFV [32, 33]. They concluded that the presence of PFV alone does not necessarily confer a poor prognosis. The authors recommended that the patients with PFV be evaluated for possible surgical treatment if light perception vision exists. The two patients who did not undergo amblyopia treatment did not progress to phthisis or enucleation within the follow-up period.
In 1999, Dass and Trese [34] described their experience in the management of 35 eyes of 27 patients with PFV. Twenty nine of 35 eyes were managed surgically. Two of these 29 eyes (6.8%) had strictly anterior PFV, and were treated with lensectomy and anterior vitrectomy. Of the remaining 27 eyes, 24 eyes underwent primary lensectomy and vitrectomy via a limbus approach as they had only posterior PFV or a combined anterior and posterior PFV. Two eyes underwent scleral buckling as their primary procedure and one eye underwent enucleation for presumed RB. In this series, 6 of 29 eyes that were managed surgically, achieved 20/60 to 20/800 vision. Two additional patients obtained fix-and-follow vision. All of these 8 eyes had posterior PFV. The authors concluded that surgical treatment of PFV can result in favorable functional and visual outcome despite posterior segment involvement.
In 2002, Anteby et al [35] reported the visual and cosmetic outcomes of 89 eyes of 89 patients with unilateral PFV accompanied by cataract. The mean age on presentation was 0.83 + 1.87 years (range, immediately after birth to 9 years) and the mean follow-up was 6.3 ± 5.7 years. Clinically and ultrasonographically, 29 patients (32.5%) had anterior PFV, 28 patients (31.4%) had posterior PFV, and the remaining 30 patients (33.7%) had combined anterior and posterior disease. Sixty-one of 89 (68.5%) eyes underwent surgery (lensectomy, anterior vitrectomy and removal of persistent hyaloid system) either via a pars plana or limbal approach, while the remaining 28 of 89 eyes (31.4%) were observed without surgery. The decision not to operate was based on the judgment of the investigators due to potential for good visual outcome without
